Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

LCT receives ethics approval for Phase IIb Parkinson’s trial

LCT receives ethics approval for Phase IIb Parkinson’s trial


3 February 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has received approval from the Northern A Health and Disability Ethics Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015.

The Phase IIb trial follows the successful Phase I/IIa trial, which showed excellent safety data and clinically and statistically significant efficacy data in patients with Parkinson’s disease one year after NTCELL treatment.

The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. The company plans to initiate the trial on 24 February 2016.

If the trial is successful the company will apply for provisional consent and launch NTCELL as the first disease modifying treatment for Parkinson’s disease in 2017.

– Ends –


Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.